Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine

June 6, 2025 Research and Development Ghent University Hospital, Osivax, Vaccine, Virology, clinical trial, influenza a

Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …
News

BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours

June 6, 2025 Research and Development BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to …
News

Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy

June 5, 2025 Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …
News
lab

Study links COVID-19 and some vaccines to increased risk of rare neurological condition

June 5, 2025 Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition

An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …
News

EU regulatory momentum could catalyse clinical trial innovation

June 5, 2025 Regulatory Affairs, Research and Development AI, Corporate, EU regulation, Hospital Management, Pharmacy, Veeva Systems

Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and …
Feature

NIPRO introduces LiniXia water treatment system for dialysis clinics

June 4, 2025 Research and Development European Renal Association (ERA) Congress, LiniXia, LiniXia PRO, NIPRO, Nephrology, dialysis clinics, water treatment

Japan-based biopharma, NIPRO, has launched LiniXia, a new reverse osmosis (RO) water treatment system for haemodialysis. It was unveiled at …
News

Evosep launches high-throughput proteomics platform Evosep Eno

June 4, 2025 Business Services, Mergers and Acquisitions, Research and Development, Translation Services Evosep, Pharmacy, biotech platform

Evosep has launched Evosep Eno, a new high-throughput separation platform designed to support next-generation workflows in liquid chromatography-mass spectrometry (LC-MS)-based …
News
cream-4713579_1920

LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition

June 3, 2025 Research and Development Dermatology, LEO Pharma, Skin, clinical trial, delgocitinib cream, rare skin condition

LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe palmoplantar pustulosis (PPP). The DELTA …
News
handshake

Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases

June 3, 2025 Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases

Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
News

New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030

June 3, 2025 Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer

For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
News
Press release

Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform

May 30, 2025 Medical Communications, Research and Development Bill and Melinda Gates Foundation, Gene Weaver, Oncology, Pharmacy, Rare Diseases, funding, gene editing

UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance its programmable gene insertion technology …
News

Ochre Bio appoints Elaine Sullivan as senior independent non-executive director

May 30, 2025 Research and Development Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director

Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …
Appointment
clinical_trials_2

NICE recommends mirikizumab (Omvoh â–¼) for previously treated moderately to severely active Crohn’s disease 1

May 30, 2025 Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab

In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
News
Press release

DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder

May 29, 2025 Research and Development DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders

Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for …
News

Ryvu Therapeutics appoints Justyna Żółtek to management board

May 29, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, chief people officer, human resources, management board, oncology

Ryvu Therapeutics has promoted Justyna Żółtek, chief people officer, to its management board. The appointment reflects the company’s focus on …
Appointment
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026